Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells

Oncology Reports

Volumn 36, Issue 1, 2016, Pages 31-42

  Seo, Hye Sook ^a   Ku, Jin Mo ^a   Choi, Han Seok ^a,b   Choi, Youn Kyung ^a   Woo, Jong Kyu ^c   Kim, Minsoo ^d   Kim, Ilhwan ^d   Na, Cha Hyeok ^d   Hur, Hansol ^d   Jang, Bo Hyoung ^a   Shin, Yong Cheol ^a   Ko, Seong Gyu ^a  

^a Kyung Hee University   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

^c Seoul National University   (South Korea)

^d Kyung Hee University Hospital   (South Korea)

Author keywords

Apoptosis; Breast cancer; HER2; p53; Quercetin; STAT3

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE; CASPASE 3; CASPASE 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE B; JANUS KINASE 1; LUCIFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; QUERCETIN; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; JAK1 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; ENZYME ACTIVATION; FEMALE; METABOLISM; MITOCHONDRION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; HUMANS; JANUS KINASE 1; MATRIX METALLOPROTEINASE 9; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; QUERCETIN; RECEPTOR, ERBB-2; STAT3 TRANSCRIPTION FACTOR;

EID: 84971468226     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4786     Document Type: Article

References (44)

1. Walters DG, Young PJ, Agus C, Knize MG, Boobis AR, Gooderham NJ and Lake BG: Cruciferous vegetable consumption alters the metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in humans. Carcinogenesis 25: 1659-1669, 2004.
2. Igura K, Ohta T, Kuroda Y and Kaji K: Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 171: 11-16, 2001.
3. Hertog MG and Hollman PC: Potential health effects of the dietary flavonol quercetin. Eur J Clin Nutr 50: 63-71, 1996.
4. Coskun O, Kanter M, Korkmaz A and Oter S: Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res 51: 117-123, 2005.
5. Boots AW, Wilms LC, Swennen EL, Kleinjans JC, Bast A and Haenen GR: In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 24: 703-710, 2008.
6. Geetha T, Malhotra V, Chopra K and Kaur IP: Antimutagenic and antioxidant/prooxidant activity of quercetin. Indian J Exp Biol 43: 61-67, 2005.
7. Sudan S and Rupasinghe HP: Quercetin-3-O-glucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells. Anticancer Res 34: 1691-1699, 2014.
8. Danihelová M, Veverka M, Sturdík E and Jantová S: Antioxidant action and cytotoxicity on HeLa and NIH-3T3 cells of new quercetin derivatives. Interdiscip Toxicol 6: 209-216, 2013.
9. Deng XH, Song HY, Zhou YF, Yuan GY and Zheng FJ: Effects of quercetin on the proliferation of breast cancer cells and expression of survivin in vitro. Exp Ther Med 6: 1155-1158, 2013.
10. van Erk MJ, Roepman P, van der Lende TR, Stierum RH, Aarts JM, van Bladeren PJ and van Ommen B: Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr 44: 143-156, 2005.
11. Murtaza I, Marra G, Schlapbach R, Patrignani A, Künzli M, Wagner U, Sabates J and Dutt A: A preliminary investigation demonstrating the effect of quercetin on the expression of genes related to cell-cycle arrest, apoptosis and xenobiotic metabolism in human CO115 colon-adenocarcinoma cells using DNA microarray. Biotechnol Appl Biochem 45: 29-36, 2006.
12. Verma AK, Johnson JA, Gould MN and Tanner MA: Inhibition of 7,12-dimethylbenz(a)anthracene- and N-nitrosomethylurea-induced rat mammary cancer by dietary flavonol quercetin. Cancer Res 48: 5754-5758, 1988.
13. Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol 35: 495-516, 2007.
14. Fan TJ, Han LH, Cong RS and Liang J: Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai) 37: 719-727, 2005.
15. Bosch M, Poulter NS, Vatovec S and Franklin-Tong VE: Initiation of programmed cell death in self-incompatibility: Role for cytoskeleton modifications and several caspase-like activities. Mol Plant 1: 879-887, 2008.
16. Zhang A, Wu Y, Lai HWL and Yew DT: Apoptosis - a brief review. Neuroembryology 3: 47-59, 2004.
17. Waring P and Müllbacher A: Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol 77: 312-317, 1999.
18. Gupta S: Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review). Int J Oncol 22: 15-20, 2003.
19. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
20. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274: 22932-22940, 1999.
21. Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ and Slamon DJ: HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res 7: R1058-R1079, 2005.
22. Joshi JP, Brown NE, Griner SE and Nahta R: Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochem Pharmacol 82: 1090-1099, 2011.
23. Favoni RE, Daga A, Malatesta P and Florio T: Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. Br J Pharmacol 166: 532-553, 2012.
24. Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, Kakeji Y and Maehara Y: Trastuzumab and breast cancer: Developments and current status. Int J Clin Oncol 11: 199-208, 2006.
25. Dean-Colomb W and Esteva FJ: Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer 44: 2806-2812, 2008.
26. Seo HS, Choi HS, Choi HS, Choi YK, Um JY, Choi I, Shin YC and Ko SG: Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-kappaB signaling in HER2-overexpressing breast cancer cells. Anticancer Res 31: 3301-3313, 2011.
27. Seo HS, Choi HS, Kim SR, Choi YK, Woo SM, Shin I, Woo JK, Park SY, Shin YC and Ko SG: Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cells. Mol Cell Biochem 366: 319-334, 2012.
28. Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK, et al: STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 19: 1296-1298, 2005.
29. Earnshaw WC, Martins LM and Kaufmann SH: Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68: 383-424, 1999.
30. Kuo PC, Liu HF and Chao JI: Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J Biol Chem 279: 55875-55885, 2004.
31. Schuler M and Green DR: Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 29: 684-688, 2001.
32. Shen Y and White E: p53-dependent apoptosis pathways. Adv Cancer Res 82: 55-84, 2001.
33. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, Depinho RA and Bonni A: Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22: 449-462, 2008.
34. Lewis HD, Winter A, Murphy TF, Tripathi S, Pandey VN and Barton BE: STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: Differential activity between 5′ and 3′ ends. Mol Cancer Ther 7: 1543-1550, 2008.
35. Kortylewski M, Jove R and Yu H: Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 24: 315-327, 2005.
36. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R and Yu H: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21: 7001-7010, 2002.
37. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66: 3188-3196, 2006.
38. Sellers LA, Feniuk W, Humphrey PP and Lauder H: Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase. Resultant effects on cell proliferation. J Biol Chem 274: 16423-16430, 1999.
39. Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, Kraker A, Krolewski JJ, Medveczky P and Jove R: Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem 275: 24935-24944, 2000.
40. Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos AS, Carter B, Turkson J and Jove R: Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 5: 621-629, 2006.
41. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
42. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD and Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613, 1996.
43. Tolaney SM and Krop IE: Mechanisms of trastuzumab resistance in breast cancer. Anticancer Agents Med Chem 9: 348-355, 2009.
44. Buzdar AU: Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol 20: 993-999, 2009.